13 March
2025
ECO Animal Health Group
plc
("ECO" or
the "Company")
R&D Day
ECO
Animal Health Group plc (AIM: EAH), a rapidly growing global
animal health company with a portfolio of marketed veterinary
products and a maturing proprietary R&D pipeline, announces
that it is hosting an R&D Day today for institutional
and private investors and analysts, with presentations
starting at 2:00pm GMT at Andaz London, 40 Liverpool
St, London EC2M 7QN.
The event will be led by David Hallas,
CEO, and Chris Wilks, CFO, alongside senior leaders from
across the Company and an industry expert. Attendees will have the
opportunity to gain valuable insights on how the next generation of
assets in ECO's R&D pipeline are driving long-term value
creation and future proofing the business through innovations in
preventative animal health.
For those who would like to join virtually,
please register via the dedicated registration page:
https://www.equitydevelopment.co.uk/news-and-events/eah-rd-investor-presentation-13march2025.
No new information will be provided on current
trading at the R&D Day. For guidance on FY25 trading, the
Company asks investors to review the outlook section of the interim
results announced on 28 November 2024 as this remains relevant. The
Company will provide a trading update for the year ending 31 March
2025 in April 2025.
Following the event, slides and a recording
will be made available for viewing on the Investors section of the
Company's website.
-Ends-
For further
information please contact:
|
ECO Animal
Health Group plc
David Hallas (CEO)
Christopher Wilks (CFO)
|
020 8447 8899
|
|
Singer Capital
Markets (Nominated Adviser & Joint Broker)
Phil Davies
Sam Butcher
|
020 7496 3000
|
|
Investec
(Joint Broker)
Gary Clarence
Lydia Zychowska
|
020 7597 5970
|
|
Equity
Development
Hannah Crowe
Matt Evans
|
020 7065 2692
|
|
ICR Healthcare
(Financial PR)
Mary-Jane Elliott
Jessica Hodgson
|
020 3709 5700
ecoanimalhealth@consilium-comms.com
|
|
|
About ECO
Animal Health
ECO Animal Health is a world leader in animal
health, developing and marketing branded veterinary pharmaceuticals
globally, with expertise in antibiotics and vaccines for pigs and
poultry. We have a maturing proprietary R&D
pipeline.
Headquartered in the UK, with global offices
including R&D and manufacturing, we have marketing
authorisations in over 70 countries and employ over 200 people
worldwide.
Our lead product, Aivlosin® is a proprietary,
patented medication which is effective against both respiratory and
intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
